Alveron Pharma raises a further EUR 3.9 million to progress first in class cyclodextrin drug
Alveron Pharma BV (Nijmegen, The Netherlands) has raised a further EUR 3.9 million to fund the continued development of OKL-1111,
A forum for researchers, students and applicants in the field of cyclodextrin technology
Alveron Pharma BV (Nijmegen, The Netherlands) has raised a further EUR 3.9 million to fund the continued development of OKL-1111,